Journal profile · Medicine-Oncology
Translational Lung Cancer Research
ISSN 2218-6751 · eISSN 2226-4477 · Society for Translational Medicine (STM) · Hong Kong · monthly · Founded 2012
Translational Lung Cancer Research: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.46; fully open access; APC about USD 1,900; median 62 days to acceptance (100 articles, last 24 months); 430 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Translational Lung Cancer Research is published by Society for Translational Medicine (STM) and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment and Lung Cancer Research Studies, together about 53.6% of its articles. Its main subfields are Pulmonary and Respiratory Medicine and Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Translational Lung Cancer Research (TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open access journal, which was founded in March 2012. TLCR is indexed by Web of Science [Science Citation Index Expanded (SCIE)], PubMed/PubMed Central, Scopus and the Chemical Abstracts Service (CAS) Databases. Published quarterly from Mar. 2012 to Jan. 2013, and bimonthly from Feb. 2013 to Dec. 2020, TLCR now follows a monthly publication model. TLCR received its latest impact factor of 3.4 for the year 2025. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer and related thoracic diseases. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Oncology
Editorial board by country: 6 in mainland China (about 13%); most named United States 21, Mainland China 6, Japan 4, Spain 4, United Kingdom 2 (45 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lung Cancer Treatments and MutationsMedicine21.3%
- Lung Cancer Diagnosis and TreatmentMedicine18.9%
- Lung Cancer Research StudiesMedicine13.4%
- Cancer Immunotherapy and BiomarkersMedicine11.1%
- Radiomics and Machine Learning in Medical ImagingMedicine5%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology3.8%
- Pleural and Pulmonary DiseasesMedicine2.6%
- Ferroptosis and cancer prognosisMedicine2.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Respiratory System | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Respiratory System | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
| Minor | Respiratory System | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of SciencePMCCASPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.46LetPub ·
- Impact factor (publisher)
- 3.4Publisher website ·
- CiteScore 2026-06
- 4.6LetPub ·
- CiteScore (publisher) 2025
- 4.6Publisher website ·
- SJR 2026-06
- 0.99LetPub ·
- SNIP 2026-06
- 0.89LetPub ·
- h-index
- 79OpenAlex ·
- i10-index
- 1,031OpenAlex ·
- 2-year mean citedness
- 2.46OpenAlex ·
- Self-citation rate
- 5.9%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 380LetPub ·
Articles by year OpenAlex count · 2,800 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 293 | 293 | 51 |
| 2025 | 430 | 430 | 990 |
| 2024 | 324 | 324 | 1,539 |
| 2023 | 244 | 244 | 2,080 |
| 2022 | 233 | 233 | 3,357 |
| 2021 | 389 | 389 | 8,668 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
62 daysMedian, submission to acceptance · P25–P75 49 days – 78 days
- Acceptance to online
- median 24 days (100 articles)
- Submission to online
- median 85 days
- Sample
- 100 articles with submission and acceptance dates (805 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 1–3 weeksLetPub ·
- Submission to publication (journal-reported)
- about 17 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 1,900 | Yes | CC BY-NC-ND |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Reference style
- Vancouver
- First submission
- Free format: the journal's layout is not required
- Suggested reviewers
- Optional
- Highlights
- Optional
- Graphical abstract
- Optional
Article types accepted20
- brief report2.7 Brief ReportLength not stated
- case reportManuscript categories Word limit Abstract Key words Main text Reference Tables and Figures Structure template Original Article No limit Structured with Backgrou…Length not stated
- case series2.4 Case SeriesLength not stated
- clinical practice guideline2.3.1 Clinical Practice GuidelineLength not stated
- clinical practice review2.2.4 Clinical Practice ReviewLength not stated
- editorial2.10.1 EditorialLength not stated
- editorial commentary2.10.2 Editorial CommentaryLength not stated
- expert consensus2.3.2 Expert ConsensusLength not stated
- images in clinical medicine2.8 Images in Clinical MedicineLength not stated
- letter to the editor2.11 Letter to the EditorLength not stated
- literature reviewManuscript categories Word limit Abstract Key words Main text Reference Tables and Figures Structure template Original Article No limit Structured with Backgrou…Length not stated
- mini-review2.2.5 Mini-ReviewLength not stated
- narrative review2.2.3 Narrative Review (Also Called Literature Review)Length not stated
- original articleManuscript categories Word limit Abstract Key words Main text Reference Tables and Figures Structure template Original Article No limit Structured with Backgrou…Length not stated
- reviewManuscript categories Word limit Abstract Key words Main text Reference Tables and Figures Structure template Original Article No limit Structured with Backgrou…Length not stated
- review articleManuscript categories Word limit Abstract Key words Main text Reference Tables and Figures Structure template Original Article No limit Structured with Backgrou…Length not stated
- scoping review2.2.2 Scoping ReviewLength not stated
- study protocol2.9 Study ProtocolLength not stated
- surgical technique2.6 Surgical TechniqueLength not stated
- systematic reviewManuscript categories Word limit Abstract Key words Main text Reference Tables and Figures Structure template Original Article No limit Structured with Backgrou…Length not stated
Policy excerpts from the journal's websiteAuthorship, Publication ethics, License & copyright, Open access, Peer review
- Authorship 3.2 Authorship and Author contributions
3.2.1 AuthorshipAuthors should meet all four of the ICMJE’s authorship criteria listed below for authorship (1):
Source ↗Publisher website ·- Publication ethics
Research misconduct policy. Model summary
Policy of Dealing with Allegations of Research Misconduct
Source ↗Publisher website ·- License & copyright 6. COPYRIGHT AND PERMISSIONS
For specifications, please refer to: https://tlcr.amegroups.org/page/about/copyright-and-permission
Source ↗Publisher website ·- Open access Open Access Statement
This journal is a peer reviewed, open access journal. All content of the journal is published under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). All articles published open access will be immediately and permanently free for all to read, download, copy and distribute as defined by the applied license.
Source ↗Publisher website ·- Peer review
ICMJE, COPE, WAME compliance; open access; plagiarism screening; research misconduct; complaints and appeals; data sharing; conflicts of interest; authorship; informed consent; human and animal rights; publication ethics; corrections and retractions; copyright and permissions; open licensing; qualit Model summary
TLCR adheres to the ICMJE’s Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals (1), COPE’s Code of Conduct and Best Practice Guidelines for Journal Editors (2), and WAME’s policy (3) for generating this author instruction.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Society for Translational Medicine (STM)
- Country or region
- Hong Kong
- Language
- English
- Frequency
- monthly
- Founded
- 2012
- ISSN
- 2218-6751
- Electronic ISSN
- 2226-4477
- Society / sponsor
- Society for Translational Medicine
- Official links
FAQ
Frequently asked questions about Translational Lung Cancer Research
What CAS zone is Translational Lung Cancer Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Translational Lung Cancer Research is in Zone 3 of Medicine, and in Zone 3 of the minor category Oncology / Respiratory System. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Translational Lung Cancer Research?
The latest impact factor listed by LetPub is 3.46; CiteScore 4.6, h-index 79.
How long does peer review take at Translational Lung Cancer Research?
Based on the dates recorded on 100 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 62 days (interquartile range 49–78 days); authors report an average review time of 1–3 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Translational Lung Cancer Research?
According to the journal's author guidelines: Reference style: Vancouver; First submission: Free format: the journal's layout is not required; Suggested reviewers: Optional; Highlights: Optional; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Translational Lung Cancer Research based?
Of the 45 board members whose country the journal's board page names, 6 (about 13%) are in mainland China; the countries named most often are United States (21), Mainland China (6) and Japan (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Translational Lung Cancer Research?
According to LetPub and DOAJ records, Translational Lung Cancer Research is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Web of Science, PMC and CAS; that list has not been checked against each database.
Is Translational Lung Cancer Research open access, and what is the APC?
Translational Lung Cancer Research is a fully open-access journal. APC about USD 1,900.
Sources and updates
The facts on this page come from LetPub, DOAJ, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .